UK suspends recruitment to Covid-19 HCQ trials

The United Kingdom has suspended recruitment to malaria drug hydroxychloroquine (HCQ) trials for the treatment or prevention of Covid-19, the country’s Medicines and Healthcare products Regulatory Agency (MHRA) announced on Tuesday.

“This means that no new participants will be recruited to these trials until further data which justifies their continuation have been provided, and any additional safety measures have been implemented,” it said.

This decision follows advice from the Commission on Human Medicines. The commission had met on June 1 and June 5 to review the data for each trial in response to MHRA requests.

The MHRA has made the decision based on various other data and reports reviewing the efficacy of the drug in treating Covid-19 patients. The results of the recovery trial that had shown no beneficial effect of hydroxychloroquine in patients hospitalised with Covid-19 had also been taken into consideration.

Apart from this, a “New England Journal of Medicine publication using hydroxychloroquine as postexposure prophylaxis of Covid-19, concluding that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection,” was also considered for making the decision to suspend recruitment into new trials.

“We have told those conducting clinical trials using hydroxychloroquine to treat or prevent Covid-19 to suspend recruitment into their trials. Neither hydroxychloroquine nor chloroquine are licensed to treat Covid-19 related symptoms or to prevent infection,” said Dr June Raine, MHRA’s CEO.

However, the MHRA has advised patients taking the drug for other illnesses to continue doing so and to report any suspected side effects from the drug-using the health agency’s Yellow Card site.

“It is important to note that patients taking hydroxychloroquine and chloroquine to treat other health conditions can continue to do so, as advised by their healthcare professional, as the balance of benefits and risks remains favourable in the licensed uses,” Raine said.

The effectiveness of the drug has been under review across the globe with many countries reconsidering the use of HCQ for the treatment of Covid-19 patients.

The US Food and Drug Administration (USFDA), for instance, revoked the emergency use authorisation (EUA) for HCQ on Monday. The agency in a directive had said that hydroxychloroquine and chloroquine were “unlikely” to be effective against Covid-19.

“Additionally, in light of the ongoing serious cardiac adverse events and other potential serious side-effects, the known and potential benefits of chloroquine and hydroxychloroquine no longer outweigh the known and potential risks for the authorised use,” the USFDA had said.

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism